A

mid a growing number of probes into drug makers and patient charities, Pfizer (PFE) has agreed to pay nearly $23.8 million to resolve charges of illegally using a supposedly independent charity to pay kickbacks to Medicare patients as a way to cover their out-of-pocket costs.

Specifically, the Department of Justice alleged that Pfizer used the Patient Access Network Foundation as a conduit to cover co-pay costs for Medicare patients taking three of its drugs, according to the settlement agreement. These drugs were Sutent and Inlyta, which both treat renal cell carcinoma, and Tikosyn, which treats arrhythmia in patients with atrial fibrillation or atrial flutter.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy